HC Wainwright reaffirmed their buy rating on shares of Acasti Pharma (NASDAQ:ACST – Free Report) in a research report report published on Thursday, Benzinga reports. They currently have a $12.00 target price on the biopharmaceutical company’s stock.
Separately, Craig Hallum boosted their price objective on Acasti Pharma from $6.00 to $8.00 and gave the company a buy rating in a research note on Thursday.
View Our Latest Report on Acasti Pharma
Acasti Pharma Stock Up 1.6 %
Acasti Pharma (NASDAQ:ACST – Get Free Report) last posted its earnings results on Friday, August 9th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.04. As a group, sell-side analysts anticipate that Acasti Pharma will post -1.14 EPS for the current year.
Institutional Investors Weigh In On Acasti Pharma
A hedge fund recently raised its stake in Acasti Pharma stock. AIGH Capital Management LLC grew its stake in Acasti Pharma Inc. (NASDAQ:ACST – Free Report) by 28.9% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 641,083 shares of the biopharmaceutical company’s stock after purchasing an additional 143,724 shares during the period. Acasti Pharma makes up approximately 0.6% of AIGH Capital Management LLC’s portfolio, making the stock its 26th biggest holding. AIGH Capital Management LLC owned about 6.82% of Acasti Pharma worth $1,883,000 at the end of the most recent reporting period. 6.08% of the stock is owned by institutional investors.
Acasti Pharma Company Profile
Acasti Pharma Inc engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia.
Featured Articles
- Five stocks we like better than Acasti Pharma
- Roth IRA Calculator: Calculate Your Potential Returns
- Simon Property REIT: A Safe Bet for Growth and Steady Dividends
- The 3 Best Retail Stocks to Shop for in August
- CarMax’s Impressive Rally: What Investors Should Watch Next
- Utilities Stocks Explained – How and Why to Invest in Utilities
- MarketBeat Week in Review – 9/23 – 9/27
Receive News & Ratings for Acasti Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acasti Pharma and related companies with MarketBeat.com's FREE daily email newsletter.